EUVIMEDEUVIMED entdecken
Crossref

NSD2 targeting reverses plasticity and drug resistance in prostate cancer.

Li, Jia J, Vasciaveo, Alessandro, Karagiannis, Dimitris, Sun, Zhen, Gretarsson, Kristjan H, Chen, Xiao und 39 weitere

Open Access CRIS of the University of Bern · 01.01.2026

DOI: 10.48620/93156 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Open Access CRIS of the University of Bern, erschienen am 01.01.2026. Verfasst von Li und 50 weiteren Autor:innen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lineage plasticity is a cancer hallmark that drives disease progression and treatment resistance1,2. Plasticity is often mediated by epigenetic mechanisms that may be reversible; however, there are few examples of such reversibility. In castration-resistant prostate cancer (CRPC), plasticity mediates resistance to androgen receptor (AR) inhibitors and progression from adenocarcinoma to aggressive subtypes, including neuroendocrine prostate cancer (CRPC-NE)3-5. Here we show that plasticity-associated treatment resistance in CRPC can be reversed through the inhibition of NSD2, a histone methyltransferase6. NSD2 upregulation in CRPC-NE correlates with poor survival outcomes, and NSD2-mediated H3K36 dimethylation regulates enhancers of genes associated with neuroendocrine differentiation. In prostate tumour organoids established from genetically engineered mice7 that recapitulate the transdifferentiation to neuroendocrine states, and in human CRPC-NE organoids, CRISPR-mediated targeting of NSD2 reverts CRPC-NE to adenocarcinoma phenotypes. Moreover, a canonical AR program is upregulated and responses to the AR inhibitor enzalutamide are restored. Pharmacological inhibition of NSD2 with a first-in-class small molecule reverses plasticity and synergizes with enzalutamide to suppress growth and promote cell death in human patient-derived organoids of multiple CRPC subtypes in culture and in xenografts. Co-targeting of NSD2 and AR may represent a new therapeutic strategy for lethal forms of CRPC that are currently recalcitrant to treatment.

Schlagwörter

NSD2castration-resistant prostate cancerneuroendocrine prostate cancerlineage plasticityandrogen receptor antagonistsenzalutamide resistanceH3K36 dimethylationhistone methyltransferaseneuroendocrine differentiationcombination therapy

Zitieren

APA

Li, J, J., Vasciaveo, Alessandro, Karagiannis, Dimitris, Sun, Zhen, Gretarsson, H, K., Chen, Xiao, Ouerfelli, Ouathek, Socciarelli, Fabio, Frankenstein, Ziv, Dong, H., …, & Shen, M. M. (2026). NSD2 targeting reverses plasticity and drug resistance in prostate cancer. Open Access CRIS of the University of Bern. https://doi.org/10.48620/93156

Vancouver

Li, J J, Vasciaveo, Alessandro, Karagiannis, Dimitris, et al. NSD2 targeting reverses plasticity and drug resistance in prostate cancer. Open Access CRIS of the University of Bern. 2026. doi:10.48620/93156

BibTeX
@article{Li2026,
  author = {Li and J, Jia and Vasciaveo and Alessandro and Karagiannis and Dimitris and Sun and Zhen and Gretarsson and H, Kristjan and Chen and Xiao and Ouerfelli and Ouathek and Socciarelli and Fabio and Frankenstein and Ziv and Dong, Hanyang and Zou and Min and Yuan and Wei and Yang and Guangli and Aizenman and M, Gabriel and Pannellini and Tania and Xu and Xinjing and Beltran and Himisha and Chen and Yu and Gardner and Kevin and Robinson and D, Brian and Bono, Johann Sebastian De and Gozani, Or and Abate-Shen and Cory and Loda, Massimo F. and Sawyers, Charles L. and Rubin, Mark A. and Califano and Andrea and Lu and Chao and Shen, Michael M.},
  title = {NSD2 targeting reverses plasticity and drug resistance in prostate cancer},
  journal = {Open Access CRIS of the University of Bern},
  year = {2026},
  doi = {10.48620/93156}
}
Kostenlos starten →